Rescheduling Hydrocodone Combination Products: Lessons from New York State

Published Online: Friday, January 24, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.
 
This is the eighth in a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Repeated requests for early refills may be a sign that a medication is being misused or diverted.
Prescriptions for opioids from the emergency room may be deescalated.
Opioids produce less pain relief and more side effects in chronic lower back pain patients with high levels of depression and anxiety.
Pharmacists and their patients can help prevent prescription drug misuse, abuse, and diversion through a new educational tool launched by the Alliance for Balanced Pain Management (AfBPM).
Latest Issues
$auto_registration$